🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Once daily Truvada®

Found 109 matching trials

Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)

PHASE4

The goal of this clinical study is to learn how safe it is to switch to an ...

Status

Completed

Location

Franco Felizarta, MD

Start Date

2023-12-13

Trial ID

NCT06104306

Treatments Being Tested

B/F/TAF

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

PHASE2

The primary objective of this study is to evaluate the efficacy of oral wee...

Status

Active Not Recruiting

Location

Pacific Oaks Medical Group

Start Date

2021-10-05

Trial ID

NCT05052996

Treatments Being Tested

ISL LEN B/F/TAF ISL/LEN FDC

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

PHASE3

The objective of this study is to evaluate the safety and efficacy of a reg...

Status

Completed

Location

University of Alabama at Birmingham

Start Date

2010-04

Trial ID

NCT01108510

Treatments Being Tested

COBI RTV ATV FTC/TDF COBI placebo RTV placebo

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

PHASE3

The goal of this clinical study is to learn about the safety and efficacy o...

Status

Active Not Recruiting

Location

University of Alabama at Birmingham

Start Date

2024-10-09

Trial ID

NCT06630286

Treatments Being Tested

ISL/LEN B/F/TAF PTM B/F/TAF PTM ISL/LEN

A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)

PHASE3

This study will investigate the safety and efficacy of MK-0518 versus efavi...

Status

Completed

Location

Multiple Locations

Start Date

2006-08

Trial ID

NCT00369941

Treatments Being Tested

MK-0518 Comparator: efavirenz Comparator: Truvada Comparator: Placebo to MK-0518 Comparator: Placebo to efavirenz

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

PHASE4

The goal of this clinical study is to provide continued access to the study...

Status

Recruiting

Location

Helios Salud

Start Date

2024-08-27

Trial ID

NCT06337032

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

PHASE3

The primary objective of this study is to evaluate the efficacy of switchin...

Status

Completed

Location

University of Alabama at Birmingham

Start Date

2018-08-28

Trial ID

NCT03631732

Treatments Being Tested

B/F/TAF NRTIs Third Agent

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

PHASE3

The primary objective of this study is to evaluate the non-inferiority of s...

Status

Completed

Location

Maricopa Integrated Health System

Start Date

2015-01-26

Trial ID

NCT02345226

Treatments Being Tested

FTC/RPV/TAF EFV/FTC/TDF Placebo EFV/FTC/TDF FTC/RPV/TAF Placebo

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

PHASE2

The goals of this clinical study are to learn more about the study drug len...

Status

Active Not Recruiting

Location

Hopital Avicenne

Start Date

2024-10-07

Trial ID

NCT06513312

Treatments Being Tested

Lenacapavir Injection Lenacapavir Tablet Emtricitabine/tenofovir disoproxil fumarate (F/TDF)

A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP

PHASE2

This international, multi-centre, double-blind vaccine study is a three-arm...

Status

Completed

Location

MRC/UVRI and LSHTM Uganda Research Unit

Start Date

2020-12-15

Trial ID

NCT04066881

Treatments Being Tested

Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48)Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48)Vaccine Group C: Saline placebo (weeks 0,4,24,48)Control PrEP:TDF/FTC once daily (weeks 0-26)Experimental PrEP:TAF/FTC once daily (weeks 0-26)

Previous Next